Selective Purine Derivatives for CB2 Agonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions such as pain, atherosclerosis, diabetic retinopathy, and ischemia-reperfusion injury lack effective therapies that target Cannabinoid Receptor 2 (CB2) agonists, which are known to have beneficial effects in pre-clinical models but require specific compounds that selectively activate CB2 with minimal CB1 activity.
Innovation Solution
Development of a compound of formula (I) that acts as a selective agonist for Cannabinoid Receptor 2, specifically designed to bind to and modulate the CB2 receptor with reduced CB1 receptor activity, addressing various therapeutic needs including pain management, fibrosis, and ischemia-reperfusion injury.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a compound is designed to activate CB2 receptors for therapeutic benefit, then efficacy in treating pain, inflammation, and fibrosis is improved, but activation of CB1 receptors may occur causing unwanted side effects
Solution Approach 1:
The patent applies local quality by designing the purine derivative compound with specific structural features (substituents at positions 2, 6, and 9 of the purine ring) that create selective affinity for CB2 receptors over CB1 receptors. This structural differentiation enables the compound to interact preferentially with CB2 receptors in peripheral tissues while minimizing interaction with CB1 receptors in the central nervous system, thereby achieving therapeutic efficacy with reduced side effects
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical parameters of the purine derivative structure, including the type of substituents (R1, R2, R3, R4, R5), their positions, and their chemical nature (halogens, alkyl groups, aryl groups, etc.). These parameter modifications allow optimization of the compound's binding affinity and selectivity profile, enabling fine-tuning of CB2 agonist activity while minimizing CB1 activation
2Reliability
If early CB2 agonist compounds are used in pre-clinical models, then beneficial effects are observed, but these compounds lack sufficient selectivity for clinical application
Solution Approach 1:
The patent applies segmentation by dividing the CB2 agonist activity into distinct structural components of the purine derivative. The core purine structure provides basic binding capability, while specific substituents at different positions (2-, 6-, and 9-positions) contribute differentially to CB2 selectivity and affinity. This modular structural approach allows systematic optimization of selectivity while maintaining therapeutic efficacy
Solution Approach 2:
The patent employs composite materials by creating a complex purine derivative molecule that combines multiple functional groups and substituents with different properties. The compound integrates a purine core with various aromatic rings, halogen atoms, alkyl groups, and heteroatoms, creating a composite molecular structure that achieves both high CB2 affinity and selective recognition, distinguishing it from earlier simpler CB2 agonists
Data Source
AI summary
The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.